An international team of scientists has made a major breakthrough in linking AIDS-like Vaccine-Acquired Immunodeficiency Syndrome (VAIDS) to Covid mRNA injections.
The groundbreaking study has uncovered the mechanism that leads to VAIDS, or vaccine-induced AIDS.
As Slay News has previously reported, experts have been raising the alarm about the phenomenon for some time.
Scientists have been warning that Covid mRNA shots have caused a global surge in cases of AIDS-like autoimmunity disorders.
Reports continue to debunk claims from the corporate media that previously dismissed reports of VAIDS as “conspiracy theories.”
Meanwhile, sleazy so-called “fact-checkers” are scrambling to convince the public that the growing body of evidence on VAIDS is just “disinformation.”
In February, a major study by the world-renowned Yale University School of Medicine also linked Covid injections to VAIDS.
The Yale researchers published the findings of their bombshell study last month.
They found that mRNA injections alter human biology to create long-term spike protein production that increases over time.
The scientists warn that the Covid mRNA vaccines trigger VAIDS.
Two of the Yale study’s co-senior authors, Harlan Krumholz and Akiko Iwasaki, have been leaders in investigating mRNA shots’ links to so-called “Long Covid.”
They believe it should be renamed “Long Vax.”
As the scientific reporting on VAIDS becomes more mainstream, the condition is increasingly being referred to as “post-vaccination syndrome” (PVS).
However, PVS is identical to the condition that experts have been warning about for some time – VAIDS.
The latest study was led by Drs. Maxine Waters (not that one), Mare Vlok, Etheresia Pretorius.
The study was a collaboration between researchers at Stellenbosch University in South Africa and the UK’s University of Liverpool.
A preprint of the study was published on Research Square.
The team found that VAIDS, or PVS, is only linked to “vaccines” and cannot be tied to COVID-19 infections or described as “Long Covid.”
The findings also suggest that Post-Infection Syndrome (PIS) may also be linked to “vaccines.”
Researchers conducted a mass spectrometry-based proteomic analysis of platelet-poor plasma (PPP) samples from 14 individuals with PVS/PIS.
All had received Pfizer’s Covid mRNA vaccine.
They were compared against 16 ostensibly healthy controls.
Using thioflavin T staining and liquid chromatography-mass spectrometry (LC-MS), the team identified and quantified protein changes.
The researchers were focusing on “microclot” formation and inflammatory/coagulopathic markers.
Comparative analyses were also made against prior “Long Covid” proteomic datasets.
The study found that people suffering from PVS or PIS had significant imbalances in proteins that control blood clotting and immune function.
Specifically, levels of key clotting proteins—coagulation factors X and XI—were more than twice as high as those found in healthy individuals.
The same was true for proteins called serum amyloid A1 and A2 (SAA1/2), which are typically elevated during inflammation.
Another protein called attractin, which is linked to damage in blood vessel linings (a condition known as endothelial dysfunction), was increased by over 2.5 times.
Attractin is also known to form amyloid-like structures—misfolded proteins that can contribute to small, sticky clots in the bloodstream.
In total, the researchers found 26 proteins that were abnormally high and 26 that were abnormally low in PV/PIS patients.
Among those that significantly decreased were important immune system regulators, including Protein S100A9 and several components of antibodies.
This drop suggests a possible weakening or misfiring of the body’s normal immune defense.
The blood of PVS, or VAIDS, patients also showed the presence of “microclots.”
The researchers described the “microclots” as tiny, persistent clots that were similar to what has been observed in people with “Long Covid.”
However, when the scientists compared the protein patterns between PVS and “Long Covid,” they found very different underlying causes.
The symptoms might look alike, but the biology behind them appears to be distinct.
Worryingly, several proteins that were elevated in PVS, such as attractin and two others known as ITIH3 and ITIH4.
They were predicted to be prone to forming amyloid deposits.
These sticky protein clumps are difficult for the body to clear and may contribute to chronic inflammation and clotting.
This confirms that PVS would involve a long-term, smoldering inflammatory process that might require different treatment strategies.
This study reveals troubling biological signals in individuals suffering from VAIDS.
The scientists uncovered evidence of sustained immune activation, coagulation disturbances, and the presence of amyloidogenic proteins.
They noted that while the symptoms of VAIDS may mirror key features of “Long Covid,” they arise via potentially distinct pathways.
The exclusive use of Pfizer’s vaccine in PVS/PIS cases and the lack of overlap with Long Covid proteomic patterns underscore the need for further investigation into vaccine-specific, dose-dependent, or host-specific risk factors.
These findings demand rigorous independent replication, as they raise urgent questions about diagnosis, treatment, and the safety profile of mRNA “vaccines.”
